These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 9501742)

  • 1. Effect of a haloperidol challenge on regional brain metabolism in neuroleptic-responsive and nonresponsive schizophrenic patients.
    Bartlett EJ; Brodie JD; Simkowitz P; Schlösser R; Dewey SL; Lindenmayer JP; Rusinek H; Wolkin A; Cancro R; Schiffer W
    Am J Psychiatry; 1998 Mar; 155(3):337-43. PubMed ID: 9501742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol.
    Holcomb HH; Cascella NG; Thaker GK; Medoff DR; Dannals RF; Tamminga CA
    Am J Psychiatry; 1996 Jan; 153(1):41-9. PubMed ID: 8540590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blunted change in cerebral glucose utilization after haloperidol treatment in schizophrenic patients with prominent negative symptoms.
    Wolkin A; Sanfilipo M; Duncan E; Angrist B; Wolf AP; Cooper TB; Brodie JD; Laska E; Rotrosen JP
    Am J Psychiatry; 1996 Mar; 153(3):346-54. PubMed ID: 8610821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of haloperidol challenge on regional cerebral glucose utilization in normal human subjects.
    Bartlett EJ; Brodie JD; Simkowitz P; Dewey SL; Rusinek H; Wolf AP; Fowler JS; Volkow ND; Smith G; Wolkin A
    Am J Psychiatry; 1994 May; 151(5):681-6. PubMed ID: 8166309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study.
    Kapur S; Remington G; Jones C; Wilson A; DaSilva J; Houle S; Zipursky R
    Am J Psychiatry; 1996 Jul; 153(7):948-50. PubMed ID: 8659621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate.
    Nyberg S; Farde L; Halldin C; Dahl ML; Bertilsson L
    Am J Psychiatry; 1995 Feb; 152(2):173-8. PubMed ID: 7840348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of methylphenidate on regional brain glucose metabolism in humans: relationship to dopamine D2 receptors.
    Volkow ND; Wang GJ; Fowler JS; Logan J; Angrist B; Hitzemann R; Lieberman J; Pappas N
    Am J Psychiatry; 1997 Jan; 154(1):50-5. PubMed ID: 8988958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
    Dresel S; Tatsch K; Dähne I; Mager T; Scherer J; Hahn K
    J Nucl Med; 1998 Jul; 39(7):1138-42. PubMed ID: 9669383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics.
    Klemm E; Grünwald F; Kasper S; Menzel C; Broich K; Danos P; Reichmann K; Krappel C; Rieker O; Briele B; Hotze AL; Möller HJ; Biersack HJ
    Am J Psychiatry; 1996 Feb; 153(2):183-90. PubMed ID: 8561197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of haloperidol dose on iodine-123-IBZM brain SPECT imaging in schizophrenic patients.
    Vallabhajosula S; Hirschowitz J; Machac J
    J Nucl Med; 1997 Feb; 38(2):203-7. PubMed ID: 9025736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Dose Reduction in Schizophrenia (DORIS) Study: a final report.
    Hirschowitz J; Hitzemann R; Piscani K; Burr G; Frecska E; Culliton D; Mann M; Curtis C
    Schizophr Res; 1997 Jan; 23(1):31-43. PubMed ID: 9050126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cortical-striatal-thalamic circuits and brain glucose metabolic activity in 70 unmedicated male schizophrenic patients.
    Siegel BV; Buchsbaum MS; Bunney WE; Gottschalk LA; Haier RJ; Lohr JB; Lottenberg S; Najafi A; Nuechterlein KH; Potkin SG
    Am J Psychiatry; 1993 Sep; 150(9):1325-36. PubMed ID: 8352343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time-dependent effects of a haloperidol challenge on energy metabolism in the normal human brain.
    Bartlett EJ; Brodie JD; Simkowitz P; Dewey SL; Rusinek H; Volkow ND; Wolf AP; Smith G; Wolkin A; Cancro R
    Psychiatry Res; 1996 Mar; 60(2-3):91-9. PubMed ID: 8723299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo.
    Gründer G; Vernaleken I; Müller MJ; Davids E; Heydari N; Buchholz HG; Bartenstein P; Munk OL; Stoeter P; Wong DF; Gjedde A; Cumming P
    Neuropsychopharmacology; 2003 Apr; 28(4):787-94. PubMed ID: 12655326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The current status of PET scanning with respect to schizophrenia.
    Sedvall G
    Neuropsychopharmacology; 1992 Aug; 7(1):41-54. PubMed ID: 1388021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia.
    Wolkin A; Barouche F; Wolf AP; Rotrosen J; Fowler JS; Shiue CY; Cooper TB; Brodie JD
    Am J Psychiatry; 1989 Jul; 146(7):905-8. PubMed ID: 2568094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toward a brain map of auditory hallucinations.
    Cleghorn JM; Franco S; Szechtman B; Kaplan RD; Szechtman H; Brown GM; Nahmias C; Garnett ES
    Am J Psychiatry; 1992 Aug; 149(8):1062-9. PubMed ID: 1353314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.
    Nyberg S; Eriksson B; Oxenstierna G; Halldin C; Farde L
    Am J Psychiatry; 1999 Jun; 156(6):869-75. PubMed ID: 10360125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine.
    Kapur S; Roy P; Daskalakis J; Remington G; Zipursky R
    Am J Psychiatry; 2001 Feb; 158(2):311-4. PubMed ID: 11156818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies.
    Alexander GE; Chen K; Pietrini P; Rapoport SI; Reiman EM
    Am J Psychiatry; 2002 May; 159(5):738-45. PubMed ID: 11986126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.